Articles By Jerry Carter

Published 1 Year Ago
Booster of Antibody Drug Discovery—Phage Display Library Technology
Booster of Antibody Drug Discovery—Phage Display Library Technology

Published 1 Year Ago
40 Billion USD Transactions, ADC Drugs Have Unlimited Potential
40 Billion USD Transactions, ADC Drugs Have Unlimited Potential

Published 1 Year Ago
New Modes of Antibody Drug Coupling—PDC, AOC, ABC, AAC, ISAC
New Modes of Antibody Drug Coupling—PDC, AOC, ABC, AAC, ISAC

Published 1 Year Ago
Collagen Lose Accelerates Cancer Development
Collagen Lose Accelerates Cancer Development

Published 1 Year Ago
Explore into Pharmacokinetics/pharmacodynamics (PK/PD) of Antibody Drugs
Explore into Pharmacokinetics/pharmacodynamics (PK/PD) of Antibody Drugs

Published 1 Year Ago
10 Q&As About Monoclonal Antibody (mAb)
10 Q&As About Monoclonal Antibody (mAb)

Published 1 Year Ago
Anti-HBV Drugs in Progress
Anti-HBV Drugs in Progress

Published 1 Year Ago
Opportunities and Challenges of IVD
The outbreak of the COVID-19 epidemic in 2020 brought unprecedented attention to the in vitro diagnostics (IVD) industry.

Published 1 Year Ago
Organoid—Improve Disease Research and Drug Development
Organoids, 3D "micro-organ models" that are prepared from different types of stem cells through self-organization, can simulate the structure and function of native organs.

Published 1 Year Ago
Why Is ADC the "Rising Star of Cancer Treatment"?
In the field of tumor therapy, antibody-drug conjugate (ADC) with both targeting and strong activities has gradually become the new focus of the industry due to its excellent performance in many indications.

Previous | 1 - 2 - 3 - 4 - 5 - 6 | Next